Anti-Aging Stack: What’s Proven, What’s Theoretical, What’s Marketing

“Anti-aging” is the application most prone to selling speculation as solution. The honest assembly is short: GHK-Cu topical for skin, a pulsatile Mod GRF+ Ipamorelin stack for recovery and body-comp, Thymosin Alpha-1 if there’s an immune-modulation case, and a clearly-labelled speculative tier (MOTS-c, Humanin, Epitalon) for users who want it without mistaking it for the load-bearing pieces.

Most anti-aging users would get more from sleep, exercise, protein, resistance training, sun protection, social connection, and a low-VO2max cardio base than from any peptide on this page. The peptides are the marginal lever. They don’t replace the foundation.

The shortlist by evidence tier

Tier 1 - load-bearing pieces (real evidence)

GHK-Cu topical (1–2% serum, daily). Maquart 1993 fibroblast / collagen data, Gruchlik 2012 in-vitro proliferation, Connectivity Map gene-signature reversal toward younger baseline. Real cosmetic data, real mechanism, real timeline (12+ weeks for visible effect). The full framing in Skin and Hair.
Pulsatile GH-axis (Mod GRF + Ipamorelin pre-bed). Sleep, recovery, modest body-comp. The IGF-1 elevation is physiologic, not supraphysiologic - this matters because the cancer-risk story scales with sustained supraphysiologic IGF-1, not physiologic pulses. Runbook in Pre-Bed GH-Secretagogue Protocol; deeper framing in GH Axis Playbook.
Thymosin Alpha-1 (1.6 mg SC twice weekly, cycle-based). Approved as Zadaxin in some countries for hep B/C and as oncology adjunct. Real immune-modulator data; the “anti-aging” positioning is extrapolated from the immune-resilience signal. For users with ongoing infection susceptibility or recovering from chemo / chronic illness, this has the cleanest case in this section.

Tier 2 - speculative mitochondrial / circadian

MOTS-c (5–10 mg SC weekly, or daily lower dose). A 16-amino-acid peptide encoded by the mitochondrial genome. Animal data on AMPK signalling, insulin sensitivity, and exercise capacity is interesting; human trials are extremely early. Practical limiter: injection sting is real and treatment-discontinuing for some users. Honest evidence tier: Limited data.
Humanin (0.25–1 mg daily, 10–20 day cycles). Another mitochondrial-encoded peptide. Cytoprotective signal in animal models; AD-related research interest. No published human safety / efficacy trials in healthy adults. Honest evidence tier: Preclinical.
Epitalon (Khavinson protocol: 10 mg daily SC for 10 days, every 6 months). Telomerase / pineal modulation claims. The Russian Khavinson long-term mortality work is the largest evidence base, mostly in Russian, replication scarcity in Western literature. Honest tier: Limited data. Where it fits: cycle-based, not daily; not a primary anti-aging tool.

What’s NOT in the stack and why

Continuous CJC-1295 DAC. Continuous supraphysiologic IGF-1 has the most concrete cancer-risk epidemiology in the catalogue. For pure anti-aging (rather than aggressive recomp), the pulsatile architecture wins on risk-to-benefit.
Continuous IGF-1 LR3. Same reason, more so. See Cancer Risk and Growth Factors.
Daily systemic GHK-Cu by injection. Topical is the validated route for cosmetic outcomes. Systemic SC GHK-Cu sits in the same risk frame as other angiogenic compounds.
BPC-157 / TB-500 routine use. They’re healing peptides; cycle them around an injury, not as background “youth maintenance.” Cumulative angiogenic exposure isn’t free.

Decision guide

Have you actually fixed sleep, training, protein, sun exposure, and social connection?
→ If not, do that first. Peptides are the marginal lever, not the foundation. None of the speculative tier rescues a structurally poor baseline.
Goal: skin / hair quality?
→ Topical GHK-Cu - full protocol in Skin and Hair.
Goal: recovery, sleep, modest body-comp?
→ Mod GRF + Ipamorelin pre-bed.
Goal: immune resilience, frequent infections, chronic- illness recovery?
→ Thymosin Alpha-1 cycles with clinical guidance where possible.
Goal: speculative mitochondrial / circadian intervention, foundation already in place?
→ MOTS-c or Humanin short cycle for the mitochondrial story, Epitalon Khavinson cycle for the circadian story. Don’t expect dramatic effects; the framing is long-horizon.
Personal cancer history or first-degree relative early- onset cancer?
→ Skip the GH-axis component and stick with topical GHK-Cu plus Thymosin Alpha-1 if indicated. See Cancer Risk and Growth Factors.

Representative stacks

Stack 1 - Practical Anti-Aging Default

Topical GHK-Cu 1–2% serum AM and PM, indefinite
Pulsatile Mod GRF 1-29 100 mcg + Ipamorelin 200 mcg pre-bed, indefinite
SPF 30+ daily on all sun-exposed skin (the cheapest anti-aging intervention, frequently skipped)
Resistance training 3+x/week, 1 g protein per kg, 7+h sleep

Stack 2 - Immune-resilience Add-On

Stack 1 base
Thymosin Alpha-1 1.6 mg SC twice weekly, 4–8 week cycles 2–3 times per year
CBC with differential at baseline and end of each cycle

Stack 3 - Speculative Mitochondrial Add-On

Stack 1 base
MOTS-c 5 mg SC once weekly, or 1–2 mg daily for 14–28 days (whichever the user tolerates - injection sting varies)
Or Humanin 0.5–1 mg SC daily, 10–20 day cycles, 2x per year
Don’t stack MOTS-c + Humanin simultaneously the first time; pick one, see if it does anything subjectively, then decide

Stack 4 - Khavinson-Style Circadian

Stack 1 base
Epitalon 10 mg SC daily for 10 days, repeated every 6 months
Frame as cycle-based intervention, not acute sleep improvement - expectations matter for honest user self-assessment

What stops people

Stacking everything continuously. The most common failure pattern. Continuous GH-axis + continuous BPC-157 + weekly MOTS-c + daily Epitalon + topical GHK-Cu + occasional IGF-1 LR3 is “maximum surface area for unintended consequences,” not a sophisticated stack.
Treating speculative-tier as proven. MOTS-c and Humanin have animal data. Epitalon has Russian-language clinical work that hasn’t been broadly replicated. Setting expectations as “maybe; subjective changes if anything” is the honest framing.
Skipping the foundation and expecting peptides to rescue. Bad sleep, no training, sun-damage exposure, poor diet - none of these is solved by any peptide on this page. Order matters: foundation first, then peptides for the margin.
Counterfeits. The speculative-tier compounds (MOTS-c, Humanin, Epitalon) are particularly susceptible because the expected effect is subtle, so non-effect from an underdosed or counterfeit vial is hard to distinguish from real-but-modest effect. See Sourcing and Verification.
Cost discipline. The speculative stack can easily run $400–800/month with no proven outcome. The pulsatile GH-axis stack runs ~$60/month with the strongest evidence in this section. Keep the cost-to-evidence ratio honest.

Monitoring

IGF-1, HbA1c, fasting glucose at baseline and quarterly if running GH-axis stack.
CBC with differential at baseline and end of Thymosin Alpha-1 cycles - lymphocyte trend is the relevant signal.
Subjective wellness journal. The cleanest signal for the speculative tier comes from journaling sleep, energy, mood, recovery. Cognitive bias is real here; written records are the discipline.
Photographs. Day zero plus quarterly. Skin quality changes are the most photographable; the rest is subjective.
Bloodwork timing in the Bloodwork Panel Cheat Sheet.

Cross-references

Skin and Hair - GHK-Cu deep-dive, the most evidence-rich slice of this stack.
GH Axis Playbook - why pulsatile beats continuous for anti-aging specifically.
Cancer Risk and Growth Factors - the per-mechanism risk frame for GHK-Cu, GH axis, and IGF-1.
Sleep and Recovery - sleep is anti-aging’s biggest free intervention.
Sourcing and Verification - especially load-bearing for the speculative tier.